- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
- You can view the full Johnson & Johnson Ratings Report.
Actelion shares led Zurich stocks higher Monday despite the company's admission that its potential blockbuster Opsumit drug failed to meet a key target in late-stage trials.
For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.